Mimotopes and Genzyme Pharmaceuticals to collaborate

By Ruth Beran
Friday, 27 January, 2006

PharmAust's (ASX:PAA) subsidiary Mimotopes and US-based Genzyme Corporation have signed a strategic alliance agreement to provide a total suite of peptide products and services to both companies' customer bases.

The exclusive and global agreement commences on February 1, 2006.

Mimotopes will supply customers with research grade peptides and related services up to the point of lead candidate identification in pre-clinical applications.

Genzyme Pharmaceuticals, a business unit of Genzyme Corporation that develops and manufactures peptide and lipid products, will supply customers with identified lead candidate peptides for pre-clinical applications through to clinical and therapeutic grade peptides and related services.

Related News

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd